Avances en el uso de Ruxolitinib en el tratamiento de la enfermedad de vitiligo

Florencia Monteforte; Javier González-Argote

doi:10.56294/sctconf2023324

Systematic reviews or meta-analyses

Published: 2023-09-21

DOI: https://doi.org/10.56294/sctconf2023324

Advances in the use of Ruxolitinib in the treatment of vitiligo disease

Abstract

Introduction: Vitiligo is an acquired autoimmune hypomelanosis, associated with a genetic component, whose expression is usually triggered by environmental factors. Its typical symptoms are hypopigmented or apigmented macules with a progressive behavior, which makes it a relatively easy pathology to diagnose. First-generation JAK inhibitors, such as ruxolitinib, baricitinib, delgotinib and tofacitinib, are less selective and inhibit different JAKs. Therefore, JAKi could expand treatment options for various inflammatory skin diseases. By reducing the effect of all cytokines that are activated by the corresponding JAK/STAT pathway, they may be more effective than classical biologics that target a single cytokine. Objectives: to describe the scientific evidence on the efficacy and safety of advances in the use of Ruxolitinib in the treatment of vitiligo disease compared to other conventional treatments or placebo, in terms of skin repigmentation, symptom improvement and occurrence of adverse events.

Material and methods: a search was performed in Pubmed, Scopus, Web of Science from January 2000 to October 2022. Selecting abstracts of cohort and case-control studies evaluating the use of Ruxolitinib in the treatment of vitiligo disease in comparison with other conventional treatments or placebo, in terms of skin repigmentation, symptom improvement and occurrence of adverse events.

Results: the results of this systematic review support the efficacy of ruxolitinib cream in the treatment of vitiligo, with significant improvements in repigmentation observed in different patient subgroups. Despite some limitations, these findings are encouraging and suggest that ruxolitinib cream may be an effective and safe treatment option for vitiligo, especially in the context of facial repigmentation. However, more research is needed to confirm these results and to better understand the mechanisms involved in this treatment. This encourages further research in this area and provides hope for patients struggling with vitiligo.

Keywords:

Vitiligo,

Janus Kinase Inhibitors,

Ruxolitinib,

Systematic Review,

How to Cite

Monteforte F, González-Argote J. Advances in the use of Ruxolitinib in the treatment of vitiligo disease. Salud, Ciencia y Tecnología - Serie de Conferencias [Internet]. 2023 Sep. 21 [cited 2024 Jul. 3];2:324. Available from: https://conferencias.saludcyt.ar/index.php/sctconf/article/view/324

Copyright Notice

The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.

Article metrics

Google scholar: See link

Metrics

Metrics Loading ...

IV Jornadas de Fundamentos y Aplicaciones de la Interdisciplina (JFAI2023)

Vol. 2 (2023)

See full issue

Revistas / Journals

Issue

About

Author Guidelines